[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"microscopic-polyangiitis-mpa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:microscopic-polyangiitis-mpa":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,78,112,149,179],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100644154","ocular-manifestations-of-granulomatosis-with-polyangiitis-100644154",false,"NCT07664709","Ocular Manifestations of Granulomatosis With Polyangiitis.","Inclusion Criteria:\n\nANCA positive vasculitis age 18- no limit patients with onset od the disease and patients already under treatment\n\n\\-\n\nExclusion Criteria:\n\n* no consent for ophthalmic examination\n* inability to udergo ophthalmic examination","ALL","18 Years",{"count":18,"type":19},70,"ESTIMATED","1 Day","OBSERVATIONAL","The current state of knowledge on ANCA-associated vasculitis (AAV) indicates that it is a group of autoimmune diseases in which small blood vessels in various organs are affected. Disease entities included in this group are granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss syndrome).\n\nThese are rare diseases, with an incidence in Europe of approximately 20-25 cases per million people per year. There is a slight predominance among men, and the risk of developing the disease increases with age.\n\nANCA antibodies play a role in the pathogenesis of the disease, and inflammation within small vessels leads to damage of the vessel walls, resulting either in rupture or occlusion of the vessel lumen. Consequently, vital organs such as the kidneys, lungs, heart, nervous system, upper respiratory tract, gastrointestinal tract, and eyes may be affected.\n\nIf the disease is not diagnosed, untreated, or treated improperly, it can lead to irreversible failure of these organs and even death. Despite appropriate treatment, AAV diseases tend to relapse; therefore, therapy consists of two phases: induction therapy and maintenance therapy.\n\nCurrent EULAR\u002FEDTA guidelines for induction treatment of AAV recommend the use of cyclophosphamide (CYC) or rituximab (RTX) in combination with glucocorticosteroids in cases of severe disease. If remission is achieved after induction therapy, maintenance treatment should be initiated with drugs such as azathioprine, mycophenolate mofetil, methotrexate, or rituximab, combined with a low dose of glucocorticosteroids. Maintenance therapy should last no less than two years.\n\nThe study will focus on ophthalmological evaluation of patients diagnosed with ANCA-associated vasculitis. In this disease, all structures of the eye may be involved. The most common ocular manifestations include scleritis, keratitis, proptosis, inflammation of orbital tissues, nasolacrimal duct obstruction, and orbital involvement leading to proptosis, double vision, and restricted eye movement.\n\nUntil recently, the disease was often fatal. However, advances in diagnostics and current pharmacological treatment options, combined with appropriately aggressive immunosuppressive therapy, have significantly improved survival, enhanced patients' quality of life, and reduced mortality. Early diagnosis and prompt initiation of appropriate therapy are crucial.",[24,25,26,27],"GPA","Vasculitis","Microscopic Polyangiitis (MPA)","Churg-Strauss Syndrome (CSS)",[29,30,31,32,33],"ocular symptoms","octa","ocular manifestations","scleritis GPA","gpa ocular involvement","RECRUITING","2026-06-17",{"date":37,"type":38},"2026-06-24","ACTUAL",{"date":40,"type":38},"2024-03-01",{"date":42,"type":19},"2026-12-31",{"name":44,"class":45},"Military Institute od Medicine National Research Institute","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":46},"100627685","phase-4-comparison-of-a-strategy-based-on-clinico-biological-monitoring-versus-pre-emptive-rituximab-treatment-in-cases-of-anca-reappearance-in-granulomatosis-with-polyangiitis-and-microscopic-polyangiitis-100627685","NCT07451847","Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis.","Comparison of Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment for ANCA Repositivation in Granulomatosis With Polyangiitis and Microscopic Polyangiitis: a Prospective, Multicenter, Randomized Controlled Study.","PREP-ANCA","Inclusion Criteria:\n\n* Adult patients aged ≥ 18 years\n* Diagnosis of granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) according to the 2022 American College of Rheumatology (ACR)\u002FEuropean Alliance of Associations for Rheumatology (EULAR) classification criteria\n* Maintenance treatment with rituximab for at least 18 months, administered as follows: a 500 mg infusion on day 1 (with an optional repeat dose on day 15), followed by 500 mg infusions every 6 months for a total of 4 to 5 doses\n* Patient in complete remission, defined as a Birmingham Vasculitis Activity Score (BVAS) of 0 at the time of randomization\n* ANCA repositivity (confirmed by antigen-specific testing) within the 3 months prior to randomization\n* Ability to provide written informed consent prior to participation\n* Affiliation to a national health insurance or social security scheme\n\nExclusion Criteria:\n\n* Diagnosis of any vasculitis other than GPA or MPA\n* Active disease relapse, defined as BVAS \\> 0\n* Acute active infection requiring hospitalization or intravenous anti-infective therapy within 4 weeks prior to screening, or oral anti-infective treatment within 2 weeks prior to screening\n* History of deep tissue infections (e.g., fasciitis, abscess, osteomyelitis, septic arthritis) within 12 months prior to inclusion\n* History of severe, chronic, or recurrent infections, or any underlying condition predisposing the patient to serious infections\n* Administration of a live vaccine within 4 weeks prior to study inclusion\n* Active malignancy or history of hematologic malignancy within the past 5 years, except for localized prostate cancer or basal cell carcinoma of the skin\n* Presence of systemic diseases for which the study treatments may have unpredictable or inappropriate consequences\n* History of severe allergic or anaphylactic reactions, or known hypersensitivity to humanized or murine monoclonal antibodies and\u002For corticosteroids\n* Known hypersensitivity to any monoclonal antibody or biologic agent\n* Patients previously deemed non-responders or failures to rituximab therapy\n* Suspicion of poor adherence to treatment or anticipated inability or refusal to comply with the required follow-up visits and procedures\n* Inability or refusal to provide written informed consent Pregnant or breastfeeding women. Women of childbearing potential must use effective contraception during the study and for 6 months after the last infusion. Breastfeeding is contraindicated during treatment and for 6 months following the final rituximab dose.",{"count":18,"type":19},"INTERVENTIONAL",[58],"PHASE4","The PREP-ANCA study seeks to establish a more personalized treatment strategy for ANCA-associated vasculitides by assessing the efficacy of pre-emptive rituximab administration upon ANCA repositivity in preventing relapses in granulomatosis with polyangiitis and microscopic polyangiitis.",[61,62,26],"ANCA Associated Vasculitis (AAV)","Polyangiitis (GPA)",[64,65,66,67],"ANCA","Granulomatosis with polyangiitis","Microscopic polyangiitis","Rituximab","NOT_YET_RECRUITING","2026-03-02",{"date":71,"type":38},"2026-03-05",{"date":73,"type":19},"2026-02",{"date":75,"type":19},"2030-02",{"name":77,"class":45},"Assistance Publique - Hôpitaux de Paris",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":56,"phases":88,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100591699","phase-3-safe-effective-therapy-with-low-dose-glucocorticoid-in-anca-associated-vasculitis-safe-low-100591699","NCT06983821","Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)","Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW) Trial","SAFE-LOW","* New diagnosis of, or relapse of, granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), consistent with Chapel-Hill consensus definitions\n* Positive ELISA test for anti-meyloperoxidase (MPO) or anti-proteinase 3 (PR3)\n* Severe kidney involvement from active AAV, characterised by both of the following:\n* eGFR \\\u003C 40ml\u002Fmin\u002F1.73m2 (Patients known to have a stable eGFR \\\u003C40 ml\u002Fmin\u002F1.73m2 for \\>3 months prior to enrollment are NOT eligible)\n* Biopsy proven at least focal necrotizing\u002Fcrescentic glomerulonephritis OR active urinary sediment by microscopy (greater than or equal to 10 red blood cells \\[RBC\\]\u002Fhigh power field with erythrocyte casts or greater than or equal to 20% dysmorphic RBCs or greater than or equal to 5% acanthocytes without an alternative cause.\n\nExclusion Criteria (any of the following)\n\n* A diagnosis of vasculitis other than GPA or MPA (including eosinophilic granulomatosis with polyangiitis, IgA vasculitis, cryoglobulinemic vasculitis, rheumatoid vasculitis)\n* Positive anti-glomerular basement membrane antibody test or renal biopsy demonstrating linear glomerular immunoglobulin deposition\n* A diagnosis of systemic lupus erythematosus or Sjögren's syndrome\n* Receipt of dialysis for \\>21 days immediately prior to randomization or prior renal transplant\n* Age \\\u003C18\n* Pregnant at time of screening\n* Treatment with \\>1 IV dose of CYC and\u002For \\>14 days PO CYC and\u002For \\>14 days of prednisone\u002Fprednisone (less than or equal to 30mg\u002Fday) and\u002For \\>1 dose of RTX within the 28 days immediately prior to randomization\n* Chronic viral infection: HIV. HBV or HCV\n* Untreated latent mycobacterium tuberculosis infection\n* Active infection at time of presentation\n* A comorbidity or condition that, in the opinion of the investigator, precludes the use of GC, CYC or RTX",{"count":87,"type":19},36,[89],"PHASE3","The purpose of this study is to determine the safety and efficacy of a therapeutic regimen consisting of 4 weeks of glucocorticoids given with a combination of the usual induction agents for ANCA-associated vasculitis. The trial will compare this regimen to the current standard of care treatment and glucocorticoid dosing for ANCA-associated vasculitis with severe kidney involvement. This trial will begin as a pilot to assess feasibility of recruitment and of adherence to the intervention.",[92,26],"Granulomatosis With Polyangiitis",[94,95,96,97,98,99,100,24,101],"ANCA-associated vasculitis","cyclophosphamide","glucoccorticoid","rituximab","vasculitis","granulomatosis with polyangiitis","microscopic polyangiitis","MPA","2026-01-28",{"date":104,"type":38},"2026-01-30",{"date":106,"type":38},"2025-11-10",{"date":108,"type":19},"2029-02",{"name":110,"class":45},"Ottawa Hospital Research Institute",2,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":15,"minAge":119,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":122,"conditions":123,"keywords":132,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":148},"100286105","clinical-transcriptomics-in-systemic-vasculitis-cutis-100286105","NCT03004326","Clinical Transcriptomics in Systemic Vasculitis (CUTIS)","CUTIS","Inclusion Criteria:\n\n* Have a cutaneous lesion (purpuric macules, palpable purpura, retiform purpura, nodules, ulcers, or urticarial) believed to be related to active vasculitis\n* Have a suspected or confirmed diagnosis of:\n\n  * Cryoglobulinemic vasculitis (CV)\n  * Drug-induced vasculitis\n  * Eosinophilic granulomatosis with polyangiitis (EGPA)\n  * IgA vasculitis\n  * Isolated cutaneous vasculitis\n  * Granulomatosis with polyangiitis (GPA)\n  * Microscopic polyangiitis (MPA)\n  * Polyarteritis nodosa (PAN)\n  * Urticarial vasculitis\n* Be willing and able to provide written informed consent (or assent for those under\n\nExclusion Criteria:\n\n* You are less than five years old\n* Considered not to be a candidate for a biopsy or have a higher risk of developing an infection, bleeding, etc., from the biopsy, or a doctor believes that the risks for you participating in this study do not outweigh the potential benefit of learning information from your biopsy\n* You have a neutrophil count (type of white blood cell) less than 1500\u002Fmm3, platelet count less than 50,000\u002Fmm3, or a hemoglobin less than 7 g\u002FdL\n* You have an uncontrolled disease that could prevent you from completing the study procedures\n* You have an active infection at or near the potential biopsy site, have poor circulation, or have bony prominence or other structure that would increase your risk of complications if you participated in this study\n* You are pregnant or nursing\n* You are not able to provide informed consent","5 Years",{"count":121,"type":19},50,"Multi-center observational study to evaluate the histopathology and transcriptome of cutaneous lesions in patients with several different types of vasculitis.",[124,125,126,127,128,129,26,130,131,25],"Cryoglobulinemic Vasculitis (CV)","Drug-induced Vasculitis","Eosinophilic Granulomatosis With Polyangiitis (EGPA)","IgA Vasculitis","Isolated Cutaneous Vasculitis","Granulomatosis With Polyangiitis (GPA)","Polyarteritis Nodosa (PAN)","Urticarial Vasculitis",[133,134,135,136,24,101,137,138],"DIV","CSS","EGPA","HSP","PAN","Wegeners","2026-01-21",{"date":141,"type":38},"2026-01-22",{"date":143,"type":38},"2017-01",{"date":145,"type":19},"2028-12",{"name":147,"class":45},"Peter Merkel",10,{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":157,"minAge":16,"maxAge":158,"enrollmentInfo":159,"targetDuration":161,"studyType":21,"phases":4,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":46},"100254637","vasculitis-pregnancy-registry-100254637","NCT02593565","Vasculitis Pregnancy Registry","The Vasculitis Pregnancy Registry (V-PREG)","V-PREG","Inclusion Criteria:\n\n1. Women 18 years of age or older with one of the following diseases may take part in the study:\n\n   * Behçet's disease;\n   * Central nervous system (CNS) vasculitis;\n   * Cryoglobulinemic vasculitis (Cryoglobulinemia);\n   * Eosinophilic granulomatosis with polyangiitis (also called Churg-Strauss Syndrome);\n   * Giant Cell (Temporal) Arteritis (GCA);\n   * Granulomatosis with polyangiitis (also called Wegener's);\n   * IgA vasculitis (Henoch-Schoenlein purpura);\n   * Microscopic polyangiitis (MPA);\n   * Polyarteritis nodosa (PAN);\n   * Takayasu's arteritis (TAK);\n   * Urticarial vasculitis;\n   * Other\u002FSuspected Diagnosis.\n2. Women must be pregnant (self-report) at the time of enrollment into the registry.\n\nExclusion Criteria:\n\n1. Non-English speaking, with the exception of people who speak Spanish, Portuguese, Italian, or Turkish.\n2. Unable to provide consent.","FEMALE","50 Years",{"count":160,"type":19},100,"12 Months","The purpose of this study is to learn about the experience of women with vasculitis who become pregnant. In particular, the study will consist of several online surveys to assess\n\n1. each woman's vasculitis severity and pregnancy-related experiences, and\n2. pregnancy outcomes.",[25,164,165,166,126,27,129,167,127,168,26,130,169,131,170],"Behcet's Disease","CNS Vasculitis","Cryoglobulinemic Vasculitis","Wegener's Granulomatosis","Henoch-Schoenlein Purpura (HSP)","Takayasu Arteritis (TAK)","Systemic Vasculitis",{"date":172,"type":38},"2026-01-23",{"date":174,"type":4},"2015-11",{"date":176,"type":19},"2027-12",{"name":178,"class":45},"University of Pennsylvania",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":186,"targetDuration":188,"studyType":21,"phases":4,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":46},"100574360","special-drug-use-results-survey-for-long-term-useavacopan-100574360","NCT06758271","Special Drug Use-results Survey for Long-term Use（Avacopan）","Special Drug Use-results Survey for Long-term Use","Inclusion Criteria:\n\n* Patients with granulomatosis with polyangiitis or microscopic polyangiitis who are treatment with avacopan",{"count":187,"type":19},250,"2 Years","The purpose of this survey is evaluating the safety and efficacy of long-term administration of avacopan for Japanese patients with microscopic polyangiitis or granulomatosis with polyangiitis under actual conditions of use.",[26,129],"2025-01-15",{"date":193,"type":38},"2025-01-17",{"date":195,"type":38},"2022-07-29",{"date":197,"type":19},"2028-05-31",{"name":199,"class":200},"Kissei Pharmaceutical Co., Ltd.","INDUSTRY"]